Tech Company Financing Transactions
Crinetics Pharmaceuticals Funding Round
Crinetics Pharmaceuticals, operating out of San Diego, secured $40 million from 5AM Ventures, Versant Ventures and Vivo Capital.
Transaction Overview
Company Name
Announced On
11/3/2015
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series A
Investors
5AM Ventures (Lead Investor) (Mason Freeman)
Versant Ventures (Steve Kaldor)
Vivo Capital (Mahendra Shah)
Proceeds Purpose
Crinetics plans to use the proceeds to advance development of its small molecule somatostatin agonist program to clinical proof-of-concept for the treatment of acromegaly, as well as to move additional programs into development.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
10222 Barnes Canyon Rd. Building #2
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Crinetics Pharmaceuticals (Nasdaq: CRNX) discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Struthers
Chief Financial Officer
Marc Wilson
Vice President
Stephen Betz
Vice President
Yun-Fei Zhu
VP - Bus. Development
Ajay Madan
Browse more venture capital transactions:
Prev: 11/3/2015: Sekai Lab venture capital transaction
Next: 11/3/2015: Moovit venture capital transaction
Share this article
About Our VC Transactions Data
We record all VC transactions involving tech companies. VC investment data records reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs